{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:39:13Z","timestamp":1791859153941,"version":"4.3.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>The antimicrobial therapy of sepsis and septic shock should be individualized based on pharmacokinetic\/pharmacodynamic (PK\/PD) parameters to deliver effective and timely treatment of life-threatening infections. We conducted a literature scoping review to identify therapeutic targets of beta-lactam antibiotics in septic pediatric patients and the strategies that have been applied to overcome sepsis-related altered pharmacokinetics and increase target attainment against susceptible pathogens. A systematic search was conducted in the MEDLINE, EMBASE and Web of Science databases to select studies conducted since 2010 with therapeutic monitoring data of beta-lactams in septic children. Last searches were performed on 02 September 2021. Two independent authors selected the studies and extracted the data. A narrative and qualitative approach was used to summarize the findings. Out of the 118 identified articles, 21 met the eligibility criteria. Population pharmacokinetic modeling was performed in 12 studies, while nine studies reported data from bedside monitoring of beta-lactams. Most studies were conducted in the United States of America (<jats:italic>n<\/jats:italic> = 9) and France (<jats:italic>n<\/jats:italic> = 5) and reported PK\/PD data of amoxicillin, ampicillin, azlocillin, aztreonam, cefazolin, cefepime, cefotaxime, ceftaroline, ceftazidime, doripenem, meropenem and piperacillin\/tazobactam. Therapeutic targets ranged from to 40% <jats:italic>f<\/jats:italic>T&amp;gt; MIC to 100% <jats:italic>f<\/jats:italic>T&amp;gt; 6 \u00d7 MIC. Prolonging the infusion time and frequency were most described strategies to increase target attainment. Monitoring beta-lactam serum concentrations in clinical practice may potentially maximize therapeutic target attainment. Further studies are required to define the therapeutic target associated with the best clinical outcomes.<\/jats:p>","DOI":"10.3389\/fped.2022.777854","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:26:47Z","timestamp":1646911607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Beta-Lactams Therapeutic Monitoring in Septic Children\u2013What Target Are We Aiming for? A Scoping Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Ronaldo","family":"Morales Junior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Otofuji","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Magno Baldin","family":"Tiguman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa D'Amaro","family":"Juodinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Carla","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Regina Cavani Jorge","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/PCC.0000000000000225","article-title":"Pediatric severe sepsis in US children's hospitals","volume":"15","author":"Balamuth","year":"2014","journal-title":"Pediatr Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/PCC.0000000000000847","article-title":"LAPSES group. Epidemiology of sepsis in children admitted to PICUs in South America","volume":"17","author":"de Souza","year":"2016","journal-title":"Pediatr Crit Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","article-title":"Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children","volume":"21","author":"Weiss","year":"2020","journal-title":"Pediatr Crit Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacists Pharmacotherapy."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of \u03b2-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1002\/jcph.1128","article-title":"Optimizing antibiotic drug therapy in pediatrics: current state and future needs","volume":"58","author":"Le","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/cc13938","article-title":"Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy","volume":"18","author":"Ulldemolins","year":"2014","journal-title":"Crit Care."},{"key":"B10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Critical Care."},{"key":"B11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1128\/AAC.01368-15","article-title":"Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children","volume":"59","author":"De Cock","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/archdischild-2019-317342","article-title":"Serum amoxicillin levels in young infants (0-59 days) with sepsis treated with oral amoxicillin","volume":"105","author":"Mir","year":"2020","journal-title":"Arch Dis Child."},{"key":"B14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/INF.0000000000002663","article-title":"Best pharmaceuticals for children act \u2013 pediatric trials network. Paradoxical antibiotic effect of ampicillin: use of a population pharmacokinetic model to evaluate a clinical correlate of the eagle effect in infants with bacteremia","volume":"39","author":"Ericson","year":"2020","journal-title":"Pediatr Infect Dis J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jac\/dkaa468","article-title":"Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study","volume":"76","author":"Wu","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children","volume":"33","author":"Cies","year":"2014","journal-title":"Pediatr Infect Dis J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1128\/AAC.02089-15","article-title":"Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children","volume":"60","author":"Nichols","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/jac\/dkx093","article-title":"Dose optimization of piperacillin\/tazobactam in critically ill children","volume":"72","author":"De Cock","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40262-018-0682-1","article-title":"Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance","volume":"58","author":"B\u00e9ranger","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2021.05.044","article-title":"Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion vs. intermittent bolus of piperacillin\/tazobactam in paediatric patients","volume":"108","author":"Chongcharoenyanon","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1128\/AAC.01045-16","article-title":"Population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants","volume":"60","author":"Leroux","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40262-017-0602-9","article-title":"Population pharmacokinetic model to optimize cefotaxime dosing regimen in critically ill children","volume":"57","author":"B\u00e9ranger","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10096-019-03535-w","article-title":"Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis","volume":"38","author":"Hartman","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/jac\/dkaa170","article-title":"Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis","volume":"75","author":"Bui","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"105868","DOI":"10.1016\/j.ejps.2021.105868","article-title":"Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis","volume":"163","author":"Li","year":"2021","journal-title":"Eur J Pharm Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/cid\/ciz1155","article-title":"Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant enterobacter sp. Carrying both klebsiella pneumoniae carbapenemase-4 and New Delhi metallo-\u03b2-lactamase-1","volume":"71","author":"Yasmin","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1097\/PCC.0000000000001497","article-title":"Ceftaroline for suspected or confirmed invasive methicillin-resistant staphylococcus aureus: a pharmacokinetic case series","volume":"19","author":"Cies","year":"2018","journal-title":"Pediatr Crit Care Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1002\/phar.1567","article-title":"Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient","volume":"35","author":"Cies","year":"2015","journal-title":"Pharmacotherapy."},{"key":"B29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5863\/1551-6776-22.4.276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5863\/1551-6776-22.6.467","article-title":"Therapeutic drug monitoring of prolonged infusion aztreonam for multi-drug resistant pseudomonas aeruginosa: a case report","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"\u03b2-lactam therapeutic drug management in the PICU","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A. guide to therapeutic drug monitoring of \u03b2-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam vs. meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e00654","DOI":"10.1128\/AAC.00654-17","article-title":"Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients","volume":"61","author":"Quinton","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"383.e1","DOI":"10.1016\/j.cmi.2018.11.020","article-title":"Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study","volume":"25","author":"Bricheux","year":"2019","journal-title":"Clin Microbiol Infect."},{"key":"B41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0446","DOI":"10.1097\/CCE.0000000000000446","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Critical Care Explorations."},{"key":"B43","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/infdis\/jiaa118","article-title":"Optimizing pharmacokinetics-pharmacodynamics of antimicrobial management in patients with sepsis: a review","volume":"222","author":"Phe","year":"2020","journal-title":"J Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cmi.2020.04.022","article-title":"Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus","volume":"27","author":"Salvador","year":"2021","journal-title":"Clinical Microbiology and Infection."},{"key":"B45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/FTD.0000000000000937","article-title":"Barriers and facilitators in the clinical implementation of beta-lactam therapeutic drug monitoring in critically ill patients: a critical review","volume":"44","author":"Abdulla","year":"2022","journal-title":"Ther Drug Monit."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.777854\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:26:49Z","timestamp":1646911609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.777854\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":45,"alternative-id":["10.3389\/fped.2022.777854"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.777854","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"article-number":"777854"}}